AIM: This study aimed to analyze the expression, clinical significance of stanniocalcin 2 in cervical carcinoma patients who were treated with radiotherapy. METHODS: Stanniocalcin 2 expression was determined by real-time PCR in 10 pairs of cervical cancer and adjacent normal cervical tissues. Tumor samples from 92 patients diagnosed from 2004 to 2007 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be cervical carcinoma without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. The samples were immunohistochemically analyzed for stanniocalcin 2 expression and survival analyses were performed. RESULTS: The tumors of cervical cancer patients had significantly increased expression of stanniocalcin 2 at mRNA level compared with adjacent normal cervical tissues. High levels of stanniocalcin 2 expression was correlated with shorter overall survival, whereas low levels of stanniocalcin 2 expression was correlated with longer overall survival (P = 0.003) and progression free survival (P = 0.001) after radiotherapy. Moreover, high expression of stanniocalcin 2 was correlated with lymph node metastasis (P = 0.002). CONCLUSION: Stanniocalcin 2 could be a useful marker for the prognosis of cervical cancer patients receiving radiotherapy. Stanniocalcin 2 may contribute to tumor development and radioresistance in cervical cancer.
AIM: This study aimed to analyze the expression, clinical significance of stanniocalcin 2 in cervical carcinomapatients who were treated with radiotherapy. METHODS:Stanniocalcin 2 expression was determined by real-time PCR in 10 pairs of cervical cancer and adjacent normal cervical tissues. Tumor samples from 92 patients diagnosed from 2004 to 2007 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be cervical carcinoma without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. The samples were immunohistochemically analyzed for stanniocalcin 2 expression and survival analyses were performed. RESULTS: The tumors of cervical cancerpatients had significantly increased expression of stanniocalcin 2 at mRNA level compared with adjacent normal cervical tissues. High levels of stanniocalcin 2 expression was correlated with shorter overall survival, whereas low levels of stanniocalcin 2 expression was correlated with longer overall survival (P = 0.003) and progression free survival (P = 0.001) after radiotherapy. Moreover, high expression of stanniocalcin 2 was correlated with lymph node metastasis (P = 0.002). CONCLUSION:Stanniocalcin 2 could be a useful marker for the prognosis of cervical cancerpatients receiving radiotherapy. Stanniocalcin 2 may contribute to tumor development and radioresistance in cervical cancer.
Authors: Anthony D Gagliardi; Evan Y W Kuo; Sanda Raulic; Graham F Wagner; Gabriel E DiMattia Journal: Am J Physiol Endocrinol Metab Date: 2004-09-14 Impact factor: 4.310
Authors: K Ishibashi; K Miyamoto; Y Taketani; K Morita; E Takeda; S Sasaki; M Imai Journal: Biochem Biophys Res Commun Date: 1998-09-18 Impact factor: 3.575
Authors: Mahesh M Kumar; Sravanthi Davuluri; Sridhar Poojar; Geetashree Mukherjee; Akhilesh Kumar Bajpai; Uttam Dungarmal Bafna; Uma K Devi; Pramod P R Kallur; Acharya K Kshitish; R S Jayshree Journal: Tumour Biol Date: 2015-10-24
Authors: Christina S Fjeldbo; Eva-Katrine Aarnes; Eirik Malinen; Gunnar B Kristensen; Heidi Lyng Journal: PLoS One Date: 2016-05-31 Impact factor: 3.240
Authors: K Yokoi; K Yamashita; S Ishii; T Tanaka; N Nishizawa; A Tsutsui; H Miura; H Katoh; T Yamanashi; M Naito; T Sato; T Nakamura; M Watanabe Journal: Br J Cancer Date: 2017-03-14 Impact factor: 7.640